Norway has among the highest incidences in the world of malignant melanoma with an accumulated risk up to the age of 75 of 2.4 % for both genders [11], while mutations in CDKN2A and CDK4 were only found in 6.9 % in a population-based study among individuals with multiple primary melanomas (MPM) [12]. This evidence concerns the gene CDKN2A and melanoma.